Gilead Sciences, Inc. vs Moderna, Inc. — Stock Comparison
Gilead Sciences, Inc. (GILD) and Moderna, Inc. (MRNA) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Gilead Sciences, Inc. holds a significant lead over Moderna, Inc. on Q·Score (8.2 vs 4.9 out of 10), led by Quality (9.3 vs 0.6) and Valuation (8.1 vs 3). Moderna, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for GILD (+17.5%) than for MRNA (-7.8%).
Q·Score Breakdown
High-quality business with 43% return on equity and 31% profit margins.
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-144% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
GILD vs MRNA: which stock scores better overall?
Based on Q·Score, Gilead Sciences, Inc. (GILD) scores 8.2/10 versus Moderna, Inc. (MRNA) at 4.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: GILD or MRNA?
Moderna, Inc. (MRNA) scores higher on Growth (8.3/10 vs 7.9/10). Gilead Sciences, Inc. reports revenue growth (4.4% YoY) while Moderna, Inc. reports (260.2% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is GILD or MRNA more attractively valued?
Gilead Sciences, Inc. (GILD) scores higher on Valuation (8.1/10 vs 3/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about GILD vs MRNA?
There are 29 analysts covering GILD with a consensus price target of $157.83, and 20 analysts covering MRNA with a consensus target of $43.20. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: GILD or MRNA?
Gilead Sciences, Inc. (GILD) scores higher on Quality (9.3/10 vs 0.6/10). Net profit margin: GILD at 31.0%, MRNA at -143.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: GILD or MRNA?
Moderna, Inc. (MRNA) scores higher on Financial Health (9.4/10 vs 7.6/10). Market beta: GILD at 0.33, MRNA at 1.06. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of GILD and MRNA?
Gilead Sciences, Inc. (GILD) has a market capitalisation of $166.8B, while Moderna, Inc. (MRNA) has a market cap of $18.6B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do GILD or MRNA pay dividends?
GILD pays a dividend yield of 2.44%, while MRNA does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →